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E-mail address: tago-mg@pha.keio.ac.jp (M. FunakJAK2 V617F mutant induces transformation through aberrant activation of various transcription
factors. We found that the expression of Aurora kinase A (Aurka) was signiﬁcantly induced by
mutant JAK2 through c-Myc expression. Interestingly, mutant JAK2 enhanced resistance to cisplatin
(CDDP)-induced DNA damage, and effectively suppressed apoptosis. Ectopic expression of Aurka in
Ba/F3 cells exhibited similar resistance to CDDP, and this required kinase activity. Conversely,
knockdown and inhibition of Aurka in cells expressing mutant JAK2 abolished the resistance to
CDDP. Taken together, Aurka is most likely critical for resistance to DNA damage in cells trans-
formed by JAK2 V617F mutant.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Janus kinase 2 (JAK2) is a non-receptor tyrosine kinase and an
essential signal transducer of various cytokine signaling, including
erythropoietin (Epo) [1]. Dysregulation of the JAK2 signaling path-
way promotes cell growth and prevents apoptosis in a variety of
hematological malignancies [2]. Recently, a novel somatic muta-
tion of JAK2, V617F, was identiﬁed in myeloproliferative neo-
plasms (MPNs), including 95% polycythemia vera (PV) patients
and 50% of patients with essential thrombocythemia (ET) and pri-
mary myeloﬁbrosis (PMF) [3].
JAK2 V617F mutant is constitutively active and induces cyto-
kine-independent survival of JAK2-deﬁcient erythroid progenitor
cells [4]. In addition, in the presence of erythropoietin receptor
(EpoR), JAK2 V617F mutant exhibits tumorigenesis in nude mice,
suggesting that JAK2 V617F mutant functions as a potent oncogene
in the presence of EpoR as a signaling scaffold [5]. Furthermore,
JAK2 V617F mutant exhibited resistance to a DNA cross-linking
drug, mitomycin C, suggesting that JAK2 V617F mutant activateschemical Societies. Published by E
poietin; EpoR, erythropoietin
ferative neoplasms; RT-PCR,
AT5, signal transducers and
TA
oshi-Tago).survival signals against apoptosis induced by not only cytokine re-
moval but also DNA damage [6]. JAK2 V617F mutant caused aber-
rant activation of various transcription factors, including signal
transducers and activators of transcription 5 (STAT5) [5], and in-
duced the expression level of c-Myc [7]. It is simple speculation
that the expression of target genes regulated by these transcription
factors should be constitutively enhanced by JAK2 V617F mutant,
and some could contribute to transformation; however, it is still
unclear which gene expression harbors an essential role in trans-
forming activity.
Aurora kinase A (Aurka) is a member of the serine/threonine
kinase family and is required for assembly of the mitotic spindle
[8]. Ampliﬁcation and overexpression of Aurka are observed in sev-
eral types of human tumors and are more frequently associated
with tumor progression as well as resistance of the cells to chemo-
therapy [9]. Recently, it has been reported that the expression of
Aurka is directly induced by c-Myc and that an Aurora kinase
inhibitor, VX-680, exhibited life-extending effectiveness in mice
transplanted with lymphoma elicited by overexpression of c-Myc
[10]. This indicates that Aurka functions as not only an important
mediator in oncogenesis caused by Myc but also as an attractive
therapeutic target for cancers [11].
Here,we found that the expressionof Aurkawas induced through
c-Mycdownstreamof JAK2V617Fmutant. In order to clarify the role
of Aurka in DNA damage-induced apoptosis, we examined the effect
of Aurka onDNA damage induced by cisplatin (CDDP). Interestingly,lsevier B.V. All rights reserved.
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Fig. 1. JAK2 V617F mutant signiﬁcantly induced expression of Aurka. Ba/F3 cells
were infected with empty virus (), wild-type JAK2 (WT), JAK2 mutant c-HA
(V617F) and EpoR. (A) Total RNAs were prepared from WT/EpoR cells and V617F/
EpoR cells cultured without Epo for 12 h. The enhanced gene expression induced by
JAK2 V617F mutant was determined by DNA array. (B) Transduced Ba/F3 cells were
left untreated or stimulated with Epo (5 U/ml) for 12 h. c-Myc mRNA, Aurka mRNA
and GAPDH mRNA were determined by RT-PCR analysis. (C) Transduced Ba/F3 cells
were left untreated or stimulated with Epo (5 U/ml) for 12 h. Cell lysates were
immunoblotted with antibodies against c-Myc, Aurka, HA or b-actin.
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CDDP of cells expressing JAK2 V617F mutant.
2. Materials and methods
2.1. Reagents
Recombinant human erythropoietin (Epo) (ESPO 3000) and
murine IL-3 were purchased from Kirin Brewery Co. and PEPRO-
TECH, respectively. CDDP and Aurora kinase inhibitor II were
purchased from Nihon-Kayaku and Calbiochem, respectively.
Anti-Aurka antibody and anti-Flag antibody (M2) were purchased
from SIGMA. Anti-b-actin antibody and anti-c-Myc antibody were
purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA,
USA). Anti-HA antibody (3F10) was purchased from Roche. Perox-
idase-conjugated rabbit anti-mouse and goat anti-rabbit secondary
antibodies were from Dako.
2.2. Plasmids
Murine Aurka N-Flag was subcloned into MSCV-Puro. Mutagen-
esis of amino acid residue, K175R in Aurka, was performed using a
site-directed mutagenesis kit (Stratagene). The sequences of oligo-
nucleotides used for constructing shRNA retroviral vector were as
follows: sh-A1: 50-gatccccgcaaagagccaaccagcaattcaagagattgctggttg
gctctttgcttttta-30 and 50-agcttaaaaagcaaagagccaaccagcaatctcttgaa
ttgctggttggctctttgcggg-30, sh-A2: 50-gatccccacattaagccagagaacttttca
agagaaagttctctggcttaatgtttttta-30 and 50-agcttaaaaaacattaagccagaga
actttctcttgaaaagttctctggcttaatgtggg-30, sh-A3: 50-gatccccacacgtacca
ggagacttattcaagagataagtctcctggtacgtgtttttta-30 and 50-agcttaaaaaac
acgtaccaggagacttatctcttgaataagtctcctggtacgtgtggg-30, sh-c-Myc:
50-gatccccgcgacgaggaagagaatttttcaagagaaaattctcttcctcgtcgcttttta-
30 and 50-agcttaaaaagcgacgaggaagagaattttctcttgaaaaattctcttcctcgtc
gcggg-30.
(Underlined sequences correspond to the sequence of murine
Aurka and c-Myc.)
2.3. Cell cultures and retroviral infection
Ba/F3 cells were infected with empty virus (), wild-type JAK2
(WT), JAK2 mutant (V617F) and EpoR, which had been established
previously [5]. Ba/F3 cells were infected with retrovirus encoding
Aurka and its kinase dead mutant (KD). Ba/F3 cells expressing
JAK2 (WT) or JAK2 mutant (V617F) and EpoR were infected with
retrovirus harboring shRNA against Luciferase (Luc), c-Myc and
Aurka. These cells were cultured in RPMI-1640 supplemented with
10% FBS and 2 ng/ml IL-3.
2.4. Ba/F3 cell growth assay
Transduced and exponentially growing Ba/F3 cells were washed
twice with PBS and incubated with RPMI-1640 supplemented with
1% FBS in the presence of IL-3 (0.01 ng/ml) or Epo (0.01 U/ml) for
the indicated periods. Living cells were counted using a Beckman
Coulter VI-Cell.
2.5. DNA fragmentation assay
Genomic DNA was prepared for gel electrophoresis as described
previously [5]. Electrophoresis was performed on a 1% (W/V) aga-
rose gel in Tris–boric acid buffer.
2.6. Immunoblotting
Cells were lysed in NP-40 lysis buffer (50 mM Tris–HCl pH 7.4,
10% glycerol, 50 mM NaCl, 0.5% sodium deoxycholate, 1% NP-40,20 mM NaF, 0.2 mM Na3VO4) supplemented with protease inhibi-
tors. Denatured samples were run on 10% SDS–PAGE and trans-
ferred to PVDF membranes. Immunoblotting was performed as
previously described [5].
2.7. Reverse transcriptase-polymerase chain reaction (RT-PCR)
RT was performed using an oligo (dT)20 primer and 2 lg total
RNA for ﬁrst-strand cDNA synthesis. The PCR primer sequences
were as follows: c-Myc 50-tgcgacgaggaagagaattt-30 (upstream)
and 50-aaccgctccacatacagtcc-30 (downstream); Aurka 50-aaacgga-
tagggaaggctgt-30(upstream) and 50-gtcttcggtcttctgcaagg-30 (down-
stream); GAPDH, 50-actccactcacggcaaattc-30 (upstream) and 50-
ccttccacaatgccaaagtt-30 (downstream).
3. Results
3.1. JAK2 V617F mutant constitutively induced Aurka expression
In order to observe the alterations of the gene expression in-
duced by JAK2 mutant (V617F), total RNA was prepared from
1886 K. Sumi et al. / FEBS Letters 585 (2011) 1884–1890WT/EpoR cells and V617F/EpoR cells cultured without Epo for 12 h
and then DNA micro array analysis was performed. Compared with
WT/EpoR cells, the induction of Aurka was observed as well as c-
Myc in V617F/EpoR cells (Fig. 1A). In cells expressing EpoR, Epo
stimulation signiﬁcantly enhanced the expression of c-Myc mRNA
and Aurka mRNA. In contrast, in V617F/EpoR cells, a high expres-
sion of c-Myc and Aurka mRNAs was observed regardless of Epo
stimulation (Fig. 1B). Furthermore, protein levels of c-Myc and
Aurka were also markedly elevated in V617F/EpoR cells in the
presence and absence of Epo stimulation (Fig. 1C).
3.2. JAK2 V617F mutant induced Aurka expression through c-Myc
activation
A recent study demonstrated that c-Myc directly induces the
expression of Aurka [10]. To investigate whether the JAK2 V617F
mutant-induced expression of Aurka is also mediated by c-Myc,
we established Ba/F3 cells expressing wild-type c-Myc and c-Myc
mutant (In373), which carries an insertion in the DNA-interacting
region and fails to bind to DNA (Fig. 2A and B) [12]. In unstimulated
cells, endogenous Aurka was slightly observed in empty virus-in-
fected cells. In contrast, while c-Myc signiﬁcantly induced the
expression of Aurka, In373 reduced the expression level of endog-
enous Aurka. Interestingly, IL-3 stimulation induced the expressionA
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Fig. 2. c-Myc is critical for JAK2 V617F mutant-induced expression of Aurka. (A) Scheme
with empty virus (), retroviruses encoding wild-type c-Myc and c-Myc inhibitory mutan
3 (2 ng/ml) for 6 h. (B) Cell lysates were immunoblotted with antibodies against c-Myc,
analysis. (D and E) WT/EpoR cells and V617F/EpoR cells were infected with retrovirus ha
Myc (sh-c-Myc). Transduced WT/EpoR cells were stimulated with Epo (1 U/ml) for 12
immunoblotted with antibodies against c-Myc, Aurka or b-actin. (E) Aurka mRNA and GA
and location of E-boxes. The regulatory regions of the murine Aurka promoter region anof endogenous c-Myc and Aurka in empty virus-infected cells.
Moreover, In373 completely inhibited IL-3-induced expression of
Aurka (Fig. 2B). In addition, whereas ectopic expression of c-Myc
and IL-3 stimulation signiﬁcantly induced the expression of Aurka
mRNA, In373 failed to induce its expression and inhibited IL-3-in-
duced expression of Aurka mRNA, suggesting that Aurka was trans-
criptionally induced by c-Myc (Fig. 2C). Furthermore, knockdown
of c-Myc signiﬁcantly resulted in a marked decrease in the levels
of Aurka mRNA and protein in both Epo-stimulated WT/EpoR cells
and unstimulated V617F/EpoR cells (Fig. 2D and E). Fig. 2F shows
the location of Myc-responsive CACGTG and CATGTG E-box
sequences in Aurka gene locus. The presence of these E-boxes sug-
gests that the expression of Aurka is most likely to be directly reg-
ulated by c-Myc downstream of JAK2 V617F mutant.
3.3. JAK2 V617F mutant reduced cisplatin sensitivity
Next, we investigated the effect of JAK2 V617F mutant on DNA
damage induced by CDDP. After CDDP treatment, while -/EpoR
cells showed high sensitivity to CDDP, WT/EpoR cells slightly re-
duced its sensitivity. Compared to these cells, in V617F/EpoR cells,
sensitivity to CDDP was signiﬁcantly reduced (Fig. 3A). Interest-
ingly, CDDP induced cell cycle arrest at the G2/M of V617F/EpoR
cells in a dose-dependent manner (Fig. 3B). Furthermore, the-
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creased in V617F/EpoR cells (Fig. 3C). According to the previous re-
port that p53 is stabilized by DNA damage and regulates apoptosis
[13], our data in Fig. 3C well ﬁt our observation that JAK2 V617F
mutant exhibits resistance to DNA damage. In addition, while
CDDP-induced activation of caspase 3 was observed in -/EpoR cells
and WT/EpoR cells, activation of caspase 3 was not detected in
V617F/EpoR cells (Fig. 3D). Also, CDDP induced DNA internucleos-
omal fragmentation in a concentration-dependent manner in -/
EpoR cells and WT/EpoR cells but not V617F/EpoR cells (Fig. 3E).
3.4. Kinase activity of Aurora kinase is required for resistance to
cisplatin
In order to investigate how Aurka functions in CDDP-induced
apoptosis, Ba/F3 cells were infected with retroviruses encodingCDDP (μg/mL)
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(Fig. 4A and B). There was no signiﬁcant difference of the prolifer-
ation rate in these cells, suggesting that Aurka is not involved in
proliferation and survival (Fig. 4C). Interestingly, compared with
Ba/F3 cells infected with empty virus (), while cells expressing
Aurka reduced sensitivity to CDDP, cells expressing Aurka KD mu-
tant slightly enhanced sensitivity to CDDP (Fig. 4D). As shown in
Fig. 4B, wild-type Aurka markedly reduced the expression of p53.
Furthermore, CDDP-induced caspase 3 activation and DNA frag-
mentation were inhibited by the expression of wild-type Aurka.
On the other hand, Aurka KD mutant enhanced the expression of
p53 more than that detected in empty virus-infected cells and, as
a result, induced lower viability and higher induction of apoptosis
in the presence of CDDP (Fig. 4B–F). These results suggest that
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1888 K. Sumi et al. / FEBS Letters 585 (2011) 1884–18903.5. Aurka is critical for resistance to cisplatin in cells expressing JAK2
V617F mutant
To gain further insight into the role of Aurka, endogenous Aurka
was knocked down in V617F/EpoR cells using shRNA. As a control,
we used the shRNA expression vector against luciferase (sh-Luc).
Two different shRNAs (sh-A2 and sh-A3) effectively reduced the
expression of Aurka in V617F/EpoR cells (Fig. 5A). The viable cells
infected with sh-Luc as a control and shRNAs for Aurka were
counted; however, there was no difference in the cell proliferation
rate (data not shown). Interestingly, knock down of Aurka mark-
edly enhanced the sensitivity to CDDP and increased the expres-
sion level of p53, compared to when infected with sh-Luc(Fig. 5A and B). In addition, in cells infected with shRNA for Aurka,
CDDP markedly induced the activation of caspase 3 and DNA frag-
mentation at a lower concentration (Fig. 5C and D). Furthermore,
we examined the effect of Aurka inhibitor on the resistance of
V617F/EpoR cells to CDDP. Interestingly, Aurka inhibitor slightly
reduced the viability of V617F/EpoR cells and signiﬁcantly en-
hanced the sensitivity of V617F/EpoR cells to CDDP (Fig. 5F). In
addition, Aurka inhibitor enhanced the expression of p53 in
V617F/EpoR cells (Fig. 5E). This observation well ﬁts the result
shown in Fig. 4 and emphasizes that kinase activity of Aurka is crit-
ical for the regulation of p53 stability. Furthermore, both the acti-
vation of caspase 3 and DNA fragmentation were slightly detected
in V617F/EpoR cells treated with Aurka inhibitor, and treatment
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in V617F/EpoR cells (Fig. 5G and H). Taken together, it is suggested
that Aurka is critical for resistance to DNA damage in cells trans-
formed by JAK2 V617F mutant and that Aurka inhibitor is an effec-
tive drug for MPNs.
4. Discussion
In the current study, we identiﬁed Aurka as an essential gene in-
duced by JAK2 V617F mutant and clariﬁed that the expression of
Aurka is regulated by c-Myc. Our results demonstrated that theexpression of c-Myc is also upregulated by JAK2 V617F mutant,
although it remains to be clariﬁed how the expression of c-Myc
is induced by JAK2 V617F mutant.
As shown in Fig. 3A, JAK2 V617F mutant causes resistance to
CDDP treatment, and this is strikingly abolished by the knockdown
of endogenous Aurka (Fig. 5B) and by inhibition of Aurka using a
speciﬁc inhibitor (Fig. 5F), suggesting that Aurka could be essential
for the resistance to CDDP treatment induced by JAK2 V617F. Inter-
estingly, the expression level of p53 was down-regulated by over-
expression of Aurka and up-regulated by knockdown of Aurka
(Figs. 4B and 5A). Previously, in vitro studies have demonstrated
1890 K. Sumi et al. / FEBS Letters 585 (2011) 1884–1890that Aurka phosphorylates p53 at Ser315, leading to its ubiquitina-
tion by Mdm2 and proteolysis. They also showed that silencing of
Aurka results in less phosphorylation of p53 at Ser315 and en-
hances the stability of p53 [14]. In the current study, we observed
that the expression level of p53 was increased when Aurka KD mu-
tant was expressed or endogenous Aurka was inhibited by its spe-
ciﬁc inhibitor (Fig. 4B and 5E), indicating that kinase activity of
Aurka strongly contributes to the instability of p53 downstream
of JAK2 V617F mutant. When considering these results, it is
thought that Aurka KD mutant functions as a dominant negative
mutant in p53 expression, although the mechanism by which Aur-
ka KD mutant inhibits the downregulation of p53 expression has
not been elucidated in this study. Moreover, Mao et al. reported
that the status of p53 locus inﬂuenced the function of Aurka by uti-
lizing p53-deﬁcient mice [15]. These reports strongly support a sig-
niﬁcant interaction between Aurka and p53; therefore, in
considering treatment for MPNs, not only examining the presence
of JAK2 V617F mutation in patients but also checking the status of
their p53 locus will become important in the future.
However, overexpression of Aurka failed to completely mimic
the effect of JAK2 V617F mutant (Fig. 4). We currently do not have
any additional data to explain this discrepancy; however, in the
course of DNA-array analysis, we observed that the expression of
FANCC mRNA was also highly elevated by JAK2 V617F mutant in
STAT5 dependently (data not shown). FANCC is closely related to
Fanconi anemia (FA), a recessive genomic instability syndrome.
In fact, when endogenous FANCC was knocked down using shRNA
in V617F/EpoR cells, sensitivity to CDDP was markedly increased,
suggesting that FANCC is also involved in resistance to CDDP
downstream of JAK2 V617F mutant (data not shown). Clariﬁcation
of the requirement of Aurka and FANCC in JAK2 V617F mutant-in-
duced resistance to DNA damage is a future problem to be
elucidated.
Previous reports have shown that the enhancement of Aurka
expression was associated with tumor progression [9]. In addition,
immortalized rodent cell lines transfected with Aurka form colo-
nies in vitro, and tumors when injected into nude mice [16], sug-
gesting that Aurka can promote transformation in certain
settings; however, conversely, in another cases, the overexpression
of Aurka induces mitotic abnormalities and hyperplasia in mam-
mary glands in transgenic mice [17]. Combining these reports, it
is difﬁcult to summarize the functions of Aurka in tumorigenesis
and tumor progression. In our study, Aurka strongly contributed
to the resistance to CDDP; however, overexpression of Aurka or ki-
nase dead mutant of Aurka (KD) in Ba/F3 cells could not induce
cytokine-independent cell growth (Fig. 4C). We also made a similar
observation that the proliferation rate of V617F/EpoR cells was not
changed when Aurka was knocked down (data not shown). In addi-
tion, we tested whether overexpression of Aurka in Ba/F3 cells
causes accumulation of 4 N DNA content in the G2/M phases of
the cell cycle, and induces polyploidy with >4N DNA content. How-
ever, the increase of aneuploidy was not observed in Ba/F3 cells
expressing not only wild-type Aurka but also the kinase dead mu-
tant of Aurka, as shown in Supplementary data Fig. S1. These datasuggest that Aurka alone is insufﬁcient to induce cellular transfor-
mation to a JAK2 V617F mutant.
In this study, it was strongly suggested that Aurka could be
essential for the progression of a tumor induced by JAK2 V617F,
and the combination of CDDP and Aurka inhibition would be effec-
tive to treat patients with MPDs induced by JAK2 V617F mutant;
therefore, Aurka is a candidate target for the development of
anti-cancer drugs.
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